Anzeige
Mehr »
Login
Montag, 29.04.2024 Börsentäglich über 12.000 News von 686 internationalen Medien
Basin Uranium: Es geht los! Der Uran-Superzyklus ist gestartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
218 Leser
Artikel bewerten:
(0)

Global Cardiac Biomarkers Market 2014-2018: Key Vendors are Abbott Laboratories, Alere, Ortho Clinical Diagnostics and Roche Diagnostics

DUBLIN, December 5, 2014 /PRNewswire/ --

Research and Markets(http://www.researchandmarkets.com/research/str4n4/global_cardiac) has announced the addition of the"Global Cardiac Biomarkers Market 2014-2018" report to their offering.

(Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

A cardiac biomarker is defined as a measurable substance that is an indicator used in the diagnosis and risk stratification related to cardiovascular disease (CVDs) such as acute coronary syndrome (ACS), coronary syndromes, myocardial infarction (MI), and heart failure. Some of the cardiac biomarkers include creatine kinase (CK) MB, troponins (cTnI and cTnT), BNP, NT-proBNP, GFAP, H-FABP, LDH isoenzymes, D-dimer, IMA, MPO, myoglobin, and sCD40L.

Cardiac biomarker assays help medical professionals to understand and differentiate between myocardial infarction and angina, which assists in the diagnosis and treatment of CVDs. The abnormal concentration of these biomarkers will act as significant predictors of an adverse cardiovascular condition. Cardiac point of care (POC) testing offers reliable measurement of cardiac biomarkers and provides results within one hour of testing. In addition to saving time, some cardiac POC tests have been modified to improve the accuracy of the measurement of enzymes to reduce operational error.

The analysts forecast the Global Cardiac Biomarkers market to grow at a CAGR of 12.75 percent over the period 2013-2018.

This report covers the present scenario and the growth prospects of the Global Cardiac Biomarkers market for the period 2014-2018. To calculate the market size, the report considers the revenue generated through the sales of devices and assays used for cardiac biomarkers to diagnose various cardiovascular diseases.

The identification of new cardiac biomarkers (H-FABP, GPBB, Urotensin II, and S-100 as potential cardiac biomarkers) and the advances being made in diagnostic technologies are some of the major trends uocoming in this market.

According to the report, one of the major factors driving this market is the increase in the incidence of cardiac disorders. This increase in the incidence of CVDs, HF, and coronary syndromes is leading to increased adoption of cardiac POC tests because they provide rapid diagnostics for analyzing the specificity of the disease.

Further, the report states that one key challenge in the market is the lack of specific measures to detect the presence of CVDs, which may have an adverse effect on patients because it may lead to incorrect diagnosis, and in serious cardiac conditions it may even cause death

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.


Key Topics Covered:

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

04. Market Research Methodology

05. Introduction

06. Market Landscape

07. Market Segmentation by Type of Assay

08. Global Troponin Assay Market

09. Global BNP & NT-proBNP Assay Market

10. Global CK-MB Assay Market

11. Global Myogloblin Assay Market

12. Market Segmentation by End-user

13. Global Cardiac Laboratory Testing Market

14. Geographical Segmentation

15. Key Leading Countries

16. Buying Criteria

17. Market Growth Drivers

18. Drivers and their Impact

19. Market Challenges

20. Impact of Drivers and Challenges

21. Market Trends

22. Trends and their Impact

23. Vendor Landscape

24. Key Vendor Analysis


Companies Mentioned:

  • Abbott Laboratories
  • Alere
  • AniBiotech
  • Axis-Shield
  • BG Medicine
  • Beckman Coulter
  • Becton
  • Biomerieux
  • Boston Scientific
  • Critical Diagnostics
  • Dickinson and Co.
  • LifeSign
  • Mitsubishi ChemicalEurope
  • Nanomix
  • Ortho Clinical Diagnostics
  • Radiometer Medical
  • Randox Laboratories
  • Response Biomedical
  • Roche Diagnostics
  • Siemens Healthcare
  • Sierra Resources International
  • Singulex
  • Thermo Scientific
  • Trinity Biotech
  • diaDexus

For more information visithttp://www.researchandmarkets.com/research/str4n4/global_cardiac


Media Contact:Laura Wood , +353-1-481-1716, press@researchandmarkets.net

Großer Insider-Report 2024 von Dr. Dennis Riedl
Wenn Insider handeln, sollten Sie aufmerksam werden. In diesem kostenlosen Report erfahren Sie, welche Aktien Sie im Moment im Blick behalten und von welchen Sie lieber die Finger lassen sollten.
Hier klicken
© 2014 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.